Is BRAF V600E Mutation of Prognostic Value in Nonmetastatic Melanoma?
Posted: Thursday, May 23, 2019
A study conducted by Faruk Tas, MD, of the University of Istanbul, Turkey, and colleagues found that overall survival in patients with stages I to III melanoma did not seem to be impacted by the BRAF V600E mutation. Published in the journal Neoplasma, these study findings were consistent with those of similar other trials.
“Even though it has no prognostic impact on overall survival in stage I-III melanoma patients, BRAF V600E mutation might indicate a reduced risk for relapse and/or metastasis in stage III patients,” the investigators concluded. “The potential role of the BRAF V600E mutation status as a prognostic indicator in nonmetastatic melanoma patients needs to be investigated in larger studies.”
The scientists analyzed data from 93 Turkish patients with stages I to III melanoma who received treatment from a single tertiary referral center (Istanbul Institute of Oncology). They used real-time polymerase chain reaction to determine whether BRAF V600E was present, Kaplan-Meier analysis to estimate survival, and log-rank statistics to measure differences in survivals.
BRAF V600E mutation was recorded in 46.2% of the patients and was heavily linked with gender, as it was seen in 79.1% of men and 20.9% of women. Most of the lesions were truncal, and regression seemed to be more common in patients with BRAF V600E–mutant disease (38.7% vs. 13.8%). Additionally, those with BRAF V600E–mutant disease were more likely to have a longer median survival time in comparison to those with BRAF V600E–wildtype disease (28.9 vs. 22.4 months, respectively).
Disclosure: The study authors reported no conflicts of interest.